Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ENTPD5 | O75356 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154032 | 1.00 | CA1 (0.40) | CA1CA2CA4CYP3A4MAPT | |
| SCHEMBL5155621 | 1.00 | CA1 (0.40) | CA1CA2CA4CYP3A4MAPT | |
| SCHEMBL10581109 | 0.84 | — | — | |
| SCHEMBL11018131 | 0.82 | MAPT (0.30) | MAPT | |
| SCHEMBL5694293 | 0.80 | — | — | |
| SCHEMBL5831610 | 0.78 | CA1 (0.39) | CA1CA2CA4KDM4EALDH1A1 | |
| SCHEMBL1380363 | 0.77 | CYP3A4 (0.41) | CA1CA2CA4CYP3A4MAPT | |
| SCHEMBL18029933 | 0.76 | — | — | |
| SCHEMBL1660636 | 0.76 | — | — | |
| SCHEMBL17971806 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4717006-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | claimed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | claimed |
| EP-1687292-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005051940-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | claimed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| EP-1129695-A1 | Cosmetic or dermatological sunscreen formulations | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| US-4608445-A | ORGANOLEPTIC | FIRMENICH SA (CH) | 1986-08-26 | — | — | US | disclosed |
| EP-0059912-B1 | PROCESS FOR PREPARING EARPLUGS OF SYNTHETIC FOAM | REHAU AG + Co (DE) | 1985-02-06 | — | — | EP | disclosed |
| EP-0081699-B1 | ALICYCLIC COMPOUNDS, THEIR USE AS PERFUME OR FLAVOURING AGENTS AND PROCESS FOR THEIR PREPARATION | FIRMENICH SA (CH) | 1985-01-23 | — | — | EP | disclosed |
| EP-0081699-A1 | Alicyclic compounds, their use as perfume or flavouring agents and process for their preparation | FIRMENICH SA (CH) | 1983-06-22 | — | — | EP | disclosed |
| EP-0059912-A1 | Process for preparing earplugs of synthetic foam | REHAU AG + Co (DE) | 1982-09-15 | — | — | EP | disclosed |
| US-4040977-A | HALOACETAMIDE OR THIOCYANOACETAMIDE-ALCOHOL-FORMALDEHYDE CONDENSATES | STERLING DRUG INC. (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | CA1 4549/4885CA2 2131/4885CA4 1763/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | CA1 4362/4885CA2 1699/4885CA4 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.